Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
04
2022
accepted:
06
07
2022
entrez:
21
7
2022
pubmed:
22
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Childhood cancer survivors (CCS) are predisposed to the onset of osteoporosis (OP). It is known that iron overload induces osteoclasts (OCs) overactivity and that the iron chelator Deferasirox (DFX) can counteract it. The Cannabinoid Receptor type 2 (CB2) and the transient receptor potential vanilloid type-1 (TRPV1) are potential therapeutic targets for OP. In this study we isolated OCs from peripheral blood of 20 CCS and investigated osteoclast biomarkers expression and iron metabolism evaluating iron release by OCs and the expression of several molecules involved in its regulation. Moreover, we analyzed the effects of CB2 and TRPV1 stimulation in combination with DFX on osteoclast activity and iron metabolism. We observed, for the first time, an osteoclast hyperactivation in CCS suggesting a role for iron in its development. Moreover, we confirmed the well-known role of CB2 and TRPV1 receptors in bone metabolism, suggesting the receptors as possible key biomarkers of bone damage. Moreover, we demonstrated a promising synergism between pharmacological compounds, stimulating CB2 or inhibiting/desensitizing TRPV1 and DFX, in counteracting osteoclast overactivity in CCS to improve their quality of life.
Identifiants
pubmed: 35862357
doi: 10.1371/journal.pone.0271730
pii: PONE-D-22-10767
pmc: PMC9302719
doi:
Substances chimiques
Biomarkers
0
CNR2 protein, human
0
Receptor, Cannabinoid, CB2
0
TRPV Cation Channels
0
TRPV1 protein, human
0
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271730Déclaration de conflit d'intérêts
No authors have competing interests.
Références
Pharmacol Res. 2020 Jul;157:104822
pubmed: 32335286
J Clin Oncol. 2018 Jul 20;36(21):2216-2222
pubmed: 29874139
Pediatr Blood Cancer. 2014 Sep;61(9):1638-43
pubmed: 24760750
J Clin Oncol. 2019 Sep 1;37(25):2217-2225
pubmed: 31169453
Biol Trace Elem Res. 2020 Jun;195(2):353-365
pubmed: 31473898
J Bone Miner Res. 2002 Jun;17(6):1073-80
pubmed: 12054163
PLoS One. 2018 Dec 3;13(12):e0208102
pubmed: 30507954
J Clin Oncol. 2004 Apr 1;22(7):1215-21
pubmed: 15051768
Int Immunol. 2017 Nov 1;29(9):401-409
pubmed: 28541437
Pharmaceuticals (Basel). 2018 Oct 18;11(4):
pubmed: 30340370
Cancer. 2017 Nov 1;123(21):4207-4214
pubmed: 28654149
Bone. 2020 Aug;137:115400
pubmed: 32380257
J Mol Med (Berl). 2006 May;84(5):349-64
pubmed: 16604332
Cancer. 2015 May 15;121(10):1540-7
pubmed: 25529481
Breast Cancer Res. 2018 Nov 15;20(1):135
pubmed: 30442190
Cancer Med. 2021 Mar;10(5):1772-1782
pubmed: 33605556
Curr Drug Targets. 2020;21(3):213-227
pubmed: 31433756
Bone. 2017 Jan;94:152-161
pubmed: 27686598
Front Physiol. 2019 Aug 21;10:1064
pubmed: 31496955
Hemodial Int. 2017 Jun;21 Suppl 1:S6-S20
pubmed: 28296010
J Cell Physiol. 2021 Jul;236(7):5108-5120
pubmed: 33319934
J Clin Oncol. 2020 Jan 20;38(3):232-247
pubmed: 31800343
Haematologica. 2014 Dec;99(12):1876-84
pubmed: 25216685
Front Endocrinol (Lausanne). 2021 Sep 13;12:704647
pubmed: 34589054
Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):696-701
pubmed: 16407142
Vitam Horm. 2019;110:17-45
pubmed: 30798811
Ann Pediatr Endocrinol Metab. 2020 Sep;25(3):137-144
pubmed: 33017885
Bone. 2009 Mar;44(3):476-84
pubmed: 19059369
Connect Tissue Res. 2018 Nov;59(6):509-522
pubmed: 29448860
Haematologica. 2020 Jan 31;105(2):260-272
pubmed: 31949017
Osteoporos Int. 2015 Feb;26(2):521-9
pubmed: 25209410
Prev Med. 2000 Dec;31(6):722-31
pubmed: 11133340
Exerc Immunol Rev. 2016;22:82-93
pubmed: 26853557
J Pediatr Hematol Oncol. 1998 May-Jun;20(3):241-5
pubmed: 9628436
Bone. 2011 May 1;48(5):997-1007
pubmed: 21237298
Drug Des Devel Ther. 2016 Jan 29;10:465-81
pubmed: 26893541
Pediatr Blood Cancer. 2020 Mar;67(3):e28106
pubmed: 31820553
Eur J Pharmacol. 2018 Mar 5;822:43-50
pubmed: 29366843
Cancer. 2020 Jan 1;126(1):202-210
pubmed: 31536650
J Clin Oncol. 2018 Jul 20;36(21):2153-2159
pubmed: 29874130
Neurosci Lett. 2020 Feb 16;720:134779
pubmed: 31981721
Immun Ageing. 2018 Jan 19;15:1
pubmed: 29387133
Nutrients. 2018 Aug 27;10(9):
pubmed: 30150549
Evid Based Complement Alternat Med. 2021 May 26;2021:6864723
pubmed: 34135983
Int J Mol Sci. 2019 Sep 10;20(18):
pubmed: 31510091
Biochem J. 2016 Nov 15;473(22):4243-4254
pubmed: 27681840
Blood. 2016 Sep 22;128(12):1555-61
pubmed: 27412888
J Pathol. 2020 May;251(1):49-62
pubmed: 32083318
Pharmacol Res. 2017 Jan;115:267-274
pubmed: 27919827
Bone Marrow Transplant. 2019 Oct;54(10):1651-1661
pubmed: 30809037
Toxicol Lett. 2019 Oct 1;313:50-59
pubmed: 31238089
J Pediatr Gastroenterol Nutr. 2020 Nov;71(5):633-640
pubmed: 33093370
Pharmacol Res. 2013 Feb;68(1):7-15
pubmed: 23142558
Bone. 2019 Mar;120:50-60
pubmed: 30304704
J Neuroendocrinol. 2008 May;20 Suppl 1:69-74
pubmed: 18426503
Free Radic Biol Med. 2021 Mar;165:1-13
pubmed: 33486088
Nat Med. 2009 Mar;15(3):259-66
pubmed: 19252502